Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis

Area of Science:

• Immunology
• Gastroenterology
• Oncology

Background:

• The gut microbiome plays a crucial role in immune homeostasis and disease pathogenesis.
• Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events, including colitis.
• Alterations in gut microbial composition are linked to ICI-induced colitis.

Purpose of the Study:

• To explore the association between gut microbiome composition and the development of ICI-induced colitis.
• To identify specific bacterial species or patterns that may predict or prevent ICI-related colitis.
• To discuss the potential of microbiome modulation, such as fecal transplantation, for managing ICI-induced colitis.

Main Methods:

• Review of existing literature on gut microbiome and ICI-induced colitis.
• Analysis of studies reporting gut microbiome profiles in patients undergoing ICI therapy.
• Examination of research on bacterial species associated with or protective against intestinal inflammation.

Main Results:

• Gut microbiome profiles show similarities across inflammatory conditions like inflammatory bowel disease.
• Certain bacterial species are associated with protection against colitis and improved cancer outcomes in ICI-treated patients.
• Other bacterial groups are linked to immune alterations that increase the risk of ICI-related colitis.

Conclusions:

• The gut microbiome is a significant factor in the pathogenesis of ICI-induced colitis.
• Targeting the gut microbiome offers a potential therapeutic strategy for managing ICI-related colitis.
• Further research is essential to fully elucidate the gut microbiome's role and develop effective interventions.